Lise Loberg, PhDSenior Principal Research Scientist, Emerging Technology Platforms at AbbVie
Dr. Loberg has 20 years’ experience in the biopharmaceutical industry. Currently she is Scientific Director in Emerging Therapeutic Platforms where she manages teams in preclinical safety, drug metabolism and pharmacokinetics, process chemistry, and formulations development to advance novel technical platforms from discovery to development. Prior to this role, she led preclinical safety development of oncology antibody-drug conjugates (ADC). Dr. Loberg has supported preclinical safety evaluation of small and large molecule compounds across all stages of development and ranging across several therapeutic areas. Dr. Loberg earned her Ph.D. in Toxicology from University of Cincinnati and worked at IIT Research Institute before joining Abbvie.